Top

Published in:

01-12-2020 | Insulins

Copeptin response to hypoglycemic stress is linked to prolactin activation in children

Authors: Juliana B. Drummond, Beatriz S. Soares, William Pedrosa, Erica L. M. Vieira, Antonio L. Teixeira, Mirjam Christ-Crain, Antonio Ribeiro-Oliveira Jr.

Published in: Pituitary | Issue 6/2020

Abstract

Purpose

The physiological role of arginine vasopressin (AVP) in the acute stress response in humans and especially in children is unclear. The aim of this study was to explore the interaction between copeptin, a well-established surrogate marker of AVP release, and anterior pituitary hormone activation in response to acute hypoglycemic stress in children and adolescents.

Methods

We conducted an exploratory single center study involving 77 children and adolescents undergoing insulin-induced hypoglycemia. Blood levels of copeptin, ACTH, cortisol, GH, prolactin, interleukin-6 (IL-6), adrenaline and noradrenaline were determined at baseline and after insulin-induced hypoglycemia.

Results

Basal plasma levels of copeptin (median: 5.2 pmol/L) increased significantly after hypoglycemia (median 9.7 pmol/L; P < 0.0001). Subjects with insufficient HPA axis response or severe GH deficiency had lower hypoglycemia-induced copeptin increase (median: 2.3 pmol/L) compared with individuals with intact pituitary response (median: 5.2 pmol/L, P = 0.02). Copeptin increase correlated significantly with the maximal increase of ACTH (r_s = 0.30; P = 0.010), cortisol (r_s = 0.33; P = 0.003), prolactin (r_s = 0.25; P = 0.03), IL-6 (r_s = 0.35; P = 0.008) and with BMI-SDS (r_s = − 0.28, P = 0.01). In multivariate regression analysis, prolactin increase was the only independent variable associated with copeptin increase (P = 0.0004).

Conclusion

Our data indicate that: (1) hypoglycemic stress elicits a marked copeptin response in children and adolescents, pointing out its role as an acute stress marker in this population; (2) stress-induced AVP/copeptin release is associated with anterior pituitary activation, mainly a prolactin response.

Christ-Crain M, Fenske W (2016) Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis. Nat Rev Endocrinol 12(3):168–176. https://doi.org/10.1038/nrendo.2015.224CrossRefPubMed

Robertson GL (1987) Physiology of ADH secretion. Kidney Int Suppl 21:S20–26PubMed

Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM (2007) The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology 148(2):849–856. https://doi.org/10.1210/en.2006-1309CrossRefPubMed

Rivier C, Vale W (1983) Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305(5932):325–327CrossRefPubMed

Gillies GE, Linton EA, Lowry PJ (1982) Corticotropin releasing activity of the new CRF is potentiated several times by vasopressin. Nature 299(5881):355–357CrossRefPubMed

Paulmyer-Lacroix O, Anglade G, Grino M (1994) Insulin-induced hypoglycaemia increases colocalization of corticotrophin-releasing factor and arginine vasopressin mRNAs in the rat hypothalamic paraventricular nucleus. J Mol Endocrinol 13(3):313–320CrossRefPubMed

Briski KP, Brandt JA (2000) Oxytocin and vasopressin neurones in principal and accessory hypothalamic magnocellular structures express Fos-immunoreactivity in response to acute glucose deprivation. J Neuroendocrinol 12(5):409–414CrossRefPubMed

Samson WK, Schell DA (1995) Oxytocin and the anterior pituitary gland. Adv Exp Med Biol 395:355–364PubMed

Erturk E, Jaffe CA, Barkan AL (1998) Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test. J Clin Endocrinol Metab 83(7):2350–2354. https://doi.org/10.1210/jcem.83.7.4980CrossRefPubMed

10.

Baylis PH, Heath DA (1977) Plasma-arginine-vasopressin response to insulin-induced hypoglycaemia. Lancet 2(8035):428–430CrossRefPubMed

11.

Baylis PH, Zerbe RL, Robertson GL (1981) Arginine vasopressin response to insulin-induced hypoglycemia in man. J Clin Endocrinol Metab 53(5):935–940. https://doi.org/10.1210/jcem-53-5-935CrossRefPubMed

12.

Erfurth EM, Hedner P, Lundin S, Ekman R (1996) Release of prolactin as well as adrenocorticotropin after administration of arginine-vasopressin to healthy men. Horm Metab Res 28(11):599–602. https://doi.org/10.1055/s-2007-979861CrossRefPubMed

13.

Korbonits M, Kaltsas G, Perry LA, Putignano P, Grossman AB, Besser GM, Trainer PJ (1999) The growth hormone secretagogue hexarelin stimulates the hypothalamo-pituitary-adrenal axis via arginine vasopressin. J Clin Endocrinol Metab 84(7):2489–2495. https://doi.org/10.1210/jcem.84.7.5811CrossRefPubMed

14.

Morgenthaler NG, Struck J, Alonso C, Bergmann A (2006) Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 52(1):112–119. https://doi.org/10.1373/clinchem.2005.060038CrossRefPubMed

15.

Fenske WK, Schnyder I, Koch G, Walti C, Pfister M, Kopp P, Fassnacht M, Strauss K, Christ-Crain M (2018) Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers. J Clin Endocrinol Metab 103(2):505–513. https://doi.org/10.1210/jc.2017-01891CrossRefPubMed

16.

Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A Jr, Drescher T, Bilz S, Vogt DR, Malzahn U, Kroiss M, Christ E, Henzen C, Fischli S, Tonjes A, Mueller B, Schopohl J, Flitsch J, Brabant G, Fassnacht M, Christ-Crain M (2018) A copeptin-based approach in the diagnosis of diabetes insipidus. N Engl J Med 379(5):428–439. https://doi.org/10.1056/NEJMoa1803760CrossRefPubMed

17.

Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J (2011) Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar States. J Clin Endocrinol Metab 96(4):1046–1052. https://doi.org/10.1210/jc.2010-2499CrossRefPubMed

18.

Winzeler B, Zweifel C, Nigro N, Arici B, Bally M, Schuetz P, Blum CA, Kelly C, Berkmann S, Huber A, Gentili F, Zadeh G, Landolt H, Mariani L, Muller B, Christ-Crain M (2015) Postoperative copeptin concentration predicts diabetes insipidus after pituitary surgery. J Clin Endocrinol Metab 100(6):2275–2282. https://doi.org/10.1210/jc.2014-4527CrossRefPubMed

19.

Mueller C, Mockel M, Giannitsis E, Huber K, Mair J, Plebani M, Thygesen K, Jaffe AS, Lindahl B, Association, E.S.C.S.G.o.B.i.C.o.t.A.C.C (2018) Use of copeptin for rapid rule-out of acute myocardial infarction. Eur Heart J Acute Cardiovasc Care 7(6):570–576. https://doi.org/10.1177/2048872617710791CrossRefPubMed

20.

Koch A, Yagmur E, Hoss A, Buendgens L, Herbers U, Weiskirchen R, Koek GH, Trautwein C, Tacke F (2018) Clinical relevance of copeptin plasma levels as a biomarker of disease severity and mortality in critically ill patients. J Clin Lab Anal 32(9):e22614. https://doi.org/10.1002/jcla.22614CrossRefPubMedPubMedCentral

21.

Smaradottir MI, Ritsinger V, Gyberg V, Norhammar A, Nasman P, Mellbin LG (2017) Copeptin in patients with acute myocardial infarction and newly detected glucose abnormalities—a marker of increased stress susceptibility? A report from the Glucose in Acute Myocardial Infarction cohort. Diabetes Vasc Dis Res 14(2):69–76. https://doi.org/10.1177/1479164116664490CrossRef

22.

Lattuca B, Sy V, Nguyen LS, Bernard M, Zeitouni M, Overtchouk P, Yan Y, Hammoudi N, Ceccaldi A, Collet JP, Kerneis M, Diallo A, Montalescot G, Silvain J (2018) Copeptin as a prognostic biomarker in acute myocardial infarction. Int J Cardiol. https://doi.org/10.1016/j.ijcard.2018.09.022CrossRefPubMed

23.

Wannamethee SG, Welsh P, Papacosta O, Lennon L, Whincup PH, Sattar N (2015) Copeptin, insulin resistance, and risk of incident diabetes in older men. J Clin Endocrinol Metab 100(9):3332–3339. https://doi.org/10.1210/JC.2015-2362CrossRefPubMedPubMedCentral

24.

Kelen D, Andorka C, Szabo M, Alafuzoff A, Kaila K, Summanen M (2017) Serum copeptin and neuron specific enolase are markers of neonatal distress and long-term neurodevelopmental outcome. PLoS ONE 12(9):e0184593. https://doi.org/10.1371/journal.pone.0184593CrossRefPubMedPubMedCentral

25.

Mohamed GB, Saed MA, Abdelhakeem AA, Salah K, Saed AM (2017) Predictive value of copeptin as a severity marker of community-acquired pneumonia. Electron Physician 9(7):4880–4885. https://doi.org/10.19082/4880CrossRefPubMedPubMedCentral

26.

Sims CA, Guan Y, Bergey M, Jaffe R, Holmes-Maguire L, Martin N, Reilly P (2017) Arginine vasopressin, copeptin, and the development of relative AVP deficiency in hemorrhagic shock. Am J Surg 214(4):589–595. https://doi.org/10.1016/j.amjsurg.2017.06.015CrossRefPubMed

27.

Tang WZ, Wang XB, Li HT, Dong M, Ji X (2017) Serum copeptin predicts severity and recurrent stroke in ischemic stroke patients. Neurotox Res 32(3):420–425. https://doi.org/10.1007/s12640-017-9754-5CrossRefPubMed

28.

Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Muller B, Christ-Crain M (2007) Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 92(7):2640–2643. https://doi.org/10.1210/jc.2006-2046CrossRefPubMed

29.

Kacheva S, Kolk K, Morgenthaler NG, Brabant G, Karges W (2015) Gender-specific co-activation of arginine vasopressin and the hypothalamic-pituitary-adrenal axis during stress. Clin Endocrinol 82(4):570–576. https://doi.org/10.1111/cen.12608CrossRef

30.

Ajala O, Lockett H, Twine G, Flanagan DE (2012) Depth and duration of hypoglycaemia achieved during the insulin tolerance test. Eur J Endocrinol 167(1):59–65. https://doi.org/10.1530/EJE-12-0068CrossRefPubMed

31.

O'Grady MJ, Hensey C, Fallon M, Hoey H, Murphy N, Costigan C, Cody D (2013) Requirement for age-specific peak cortisol responses to insulin-induced hypoglycaemia in children. Eur J Endocrinol 169(2):139–145. https://doi.org/10.1530/EJE-13-0084CrossRefPubMed

32.

Kazlauskaite R, Maghnie M (2010) Pitfalls in the diagnosis of central adrenal insufficiency in children. Endocr Dev 17:96–107. https://doi.org/10.1159/000262532CrossRefPubMed

33.

Bonfig W, Bechtold S, Bachmann S, Putzker S, Fuchs O, Pagel P, Schwarz HP (2008) Reassessment of the optimal growth hormone cut-off level in insulin tolerance testing for growth hormone secretion in patients with childhood-onset growth hormone deficiency during transition to adulthood. J Pediatr Endocrinol Metab 21(11):1049–1056CrossRefPubMed

34.

Guzzetti C, Ibba A, Pilia S, Beltrami N, Di Iorgi N, Rollo A, Fratangeli N, Radetti G, Zucchini S, Maghnie M, Cappa M, Loche S (2016) Cut-off limits of the peak GH response to stimulation tests for the diagnosis of GH deficiency in children and adolescents: study in patients with organic GHD. Eur J Endocrinol 175(1):41–47. https://doi.org/10.1530/EJE-16-0105CrossRefPubMed

35.

Secco A, di Iorgi N, Napoli F, Calandra E, Calcagno A, Ghezzi M, Frassinetti C, Fratangeli N, Parodi S, Benassai M, Leitner Y, Gastaldi R, Lorini R, Maghnie M, Radetti G (2009) Reassessment of the growth hormone status in young adults with childhood-onset growth hormone deficiency: reappraisal of insulin tolerance testing. J Clin Endocrinol Metab 94(11):4195–4204. https://doi.org/10.1210/jc.2009-0602CrossRefPubMed

36.

Tuli G, Tessaris D, Einaudi S, Matarazzo P, De Sanctis L (2018) Copeptin role in polyuria-polydipsia syndrome differential diagnosis and reference range in paediatric age. Clin Endocrinol 88(6):873–879. https://doi.org/10.1111/cen.13583CrossRef

37.

Lewandowski KC, Lewinski A, Skowronska-Jozwiak E, Malicka K, Horzelski W, Brabant G (2017) Copeptin as a marker of an altered CRH axis in pituitary disease. Endocrine 57(3):474–480. https://doi.org/10.1007/s12020-017-1366-6CrossRefPubMedPubMedCentral

38.

Barron WM, Schreiber J, Lindheimer MD (1986) Effect of ovarian sex steroids on osmoregulation and vasopressin secretion in the rat. Am J Physiol 250(4 Pt 1):E352–361. https://doi.org/10.1152/ajpendo.1986.250.4.E352CrossRefPubMed

39.

Sar M, Stumpf WE (1980) Simultaneous localization of [3H]estradiol and neurophysin I or arginine vasopressin in hypothalamic neurons demonstrated by a combined technique of dry-mount autoradiography and immunohistochemistry. Neurosci Lett 17(1–2):179–184. https://doi.org/10.1016/0304-3940(80)90081-6CrossRefPubMed

40.

Stachenfeld NS, Splenser AE, Calzone WL, Taylor MP, Keefe DL (2001) Sex differences in osmotic regulation of AVP and renal sodium handling. J Appl Physiol 91(4):1893–1901. https://doi.org/10.1152/jappl.2001.91.4.1893CrossRefPubMed

41.

Lewandowski KC, Lewinski A, Skowronska-Jozwiak E, Stasiak M, Horzelski W, Brabant G (2016) Copeptin under glucagon stimulation. Endocrine 52(2):344–351. https://doi.org/10.1007/s12020-015-0783-7CrossRefPubMed

42.

Reis FM, Ribeiro-de-Oliveira Junior A, Machado LJ, Guerra RM, Reis AM, Coimbra CC (1998) Plasma prolactin and glucose alterations induced by surgical stress: a single or dual response? Exp Physiol 83(1):1–10CrossRefPubMed

43.

Delitala G, Tomasi P, Virdis R (1987) Prolactin, growth hormone and thyrotropin-thyroid hormone secretion during stress states in man. Baillieres Clin Endocrinol Metab 1(2):391–414CrossRefPubMed

44.

May PB, Burrow GN, Kayne RD, Donabedian RK (1978) Hypoglycemia-induced prolactin release. Arch Intern Med 138(6):918–920CrossRefPubMed

45.

Woolf PD, Lee LA, Leebaw W, Thompson D, Lilavivathana U, Brodows R, Campbell R (1977) Intracellular glucopenia causes prolactin release in man. J Clin Endocrinol Metab 45(3):377–383. https://doi.org/10.1210/jcem-45-3-377CrossRefPubMed

46.

Okajima T, Motomatsu T, Kato K, Ibayashi H (1980) Naloxone inhibits prolactin and growth hormone release induced by intracellular glucopenia in the rats. Life Sci 27(9):755–760. https://doi.org/10.1016/0024-3205(80)90329-xCrossRefPubMed

47.

Blask DE, Vaughan MK, Champney TH, Johnson LY, Vaughan GM, Becker RA, Reiter RJ (1984) Opioid and dopamine involvement in prolactin release induced by arginine vasotocin and vasopressin in the male rat. Neuroendocrinology 38(1):56–61. https://doi.org/10.1159/000123866CrossRefPubMed

48.

Kjaer A, Knigge U, Jorgensen H, Warberg J (1998) Selective inhibition of magnocellular vasopressin neurons by hypoosmolality: effect on histamine- and stress-induced secretion of adrenocorticotropin and prolactin. Neuroendocrinology 67(5):330–335. https://doi.org/10.1159/000054331CrossRefPubMed

49.

Mai LM, Pan JT (1990) Paradoxical effects of oxytocin and vasopressin on basal prolactin secretion and the estrogen-induced prolactin surge. Life Sci 47(14):1243–1251CrossRefPubMed

50.

Berczi I, Quintanar-Stephano A, Kovacs K (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci 1153:220–239. https://doi.org/10.1111/j.1749-6632.2008.03975.xCrossRefPubMed

51.

Shin SH (1982) Vasopressin has a direct effect on prolactin release in male rats. Neuroendocrinology 34(1):55–58. https://doi.org/10.1159/000123277CrossRefPubMed

52.

Nagy G, Mulchahey JJ, Smyth DG, Neill JD (1988) The glycopeptide moiety of vasopressin-neurophysin precursor is neurohypophysial prolactin releasing factor. Biochem Biophys Res Commun 151(1):524–529CrossRefPubMed

53.

Flores CM, Munoz D, Soto M, Kausel G, Romero A, Figueroa J (2007) Copeptin, derived from isotocin precursor, is a probable prolactin releasing factor in carp. Gen Comp Endocrinol 150(2):343–354. https://doi.org/10.1016/j.ygcen.2006.09.005CrossRefPubMed

54.

Hyde JF, North WG, Ben-Jonathan N (1989) The vasopressin-associated glycopeptide is not a prolactin-releasing factor: studies with lactating Brattleboro rats. Endocrinology 125(1):35–40. https://doi.org/10.1210/endo-125-1-35CrossRefPubMed

55.

Mukherjee A, Murray RD, Columb B, Gleeson HK, Shalet SM (2003) Acquired prolactin deficiency indicates severe hypopituitarism in patients with disease of the hypothalamic-pituitary axis. Clin Endocrinol 59(6):743–748. https://doi.org/10.1046/j.1365-2265.2003.01916.xCrossRef

56.

Chikanza IC, Petrou P, Chrousos G (2000) Perturbations of arginine vasopressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci 917:825–834CrossRefPubMed

57.

Chikanza IC, Grossman AS (1998) Hypothalamic-pituitary-mediated immunomodulation: arginine vasopressin is a neuroendocrine immune mediator. Br J Rheumatol 37(2):131–136CrossRefPubMed

58.

Drummond JB, Barbosa IG, Dantzer R, Teixeira AL (2018) The effect of insulin-induced hypoglycemia on inflammatory markers: a systematic review. Brain Behav Immun 73:41–50. https://doi.org/10.1016/j.bbi.2018.05.003CrossRefPubMed

59.

Maravic-Stojkovic V, Lausevic-Vuk LJ, Obradovic M, Jovanovic P, Tanaskovic S, Stojkovic B, Isenovic RE, Radak DJ (2014) Copeptin level after carotid endarterectomy and perioperative stroke. Angiology 65(2):122–129. https://doi.org/10.1177/0003319712473637CrossRefPubMed

60.

Masajtis-Zagajewska A, Kurnatowska I, Wajdlich M, Nowicki M (2015) Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections. BMC Urol 15:67. https://doi.org/10.1186/s12894-015-0061-2CrossRefPubMedPubMedCentral

61.

Herrero-Puente P, Prieto-Garcia B, Garcia-Garcia M, Jacob J, Martin-Sanchez FJ, Pascual-Figal D, Bueno H, Gil V, Llorens P, Vazquez-Alvarez J, Romero-Pareja R, Sanchez-Gonzalez M, Miro O (2017) Predictive capacity of a multimarker strategy to determine short-term mortality in patients attending a hospital emergency Department for acute heart failure BIO-EAHFE study. Clin Chim Acta 466:22–30. https://doi.org/10.1016/j.cca.2017.01.003CrossRefPubMed

Title: Copeptin response to hypoglycemic stress is linked to prolactin activation in children
Authors: Juliana B. Drummond
Beatriz S. Soares
William Pedrosa
Erica L. M. Vieira
Antonio L. Teixeira
Mirjam Christ-Crain
Antonio Ribeiro-Oliveira Jr.
Publication date: 01-12-2020
Publisher: Springer US
Keywords: Insulins
Hypoglycemia
Insulins
Published in: Pituitary / Issue 6/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-020-01076-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2020

Granular cell tumors of the sellar region: what should be done after subtotal resection? A systematic review

Ectopic hyperprolactinaemia due to a malignant uterine tumor resembling ovarian sex cord tumors (UTROCST)

Pituitary apoplexy associated with acute COVID-19 infection and pregnancy

Secondary pituitary hormonal dysfunction patterns: tumor size and subtype matter

The importance of specialized sleep investigations in children with a suprasellar tumor

Ectopic pituitary adenomas: clinical features, diagnostic challenges and management

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage